Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
Timothy SpelmanGabrielle SimoneauRobert HydeRobert KuheljRaed AlroughaniSerkan OzakbasRana KarabudakBassem I YamoutSamia J KhouryMurat TerziCavit BozDana HorakovaEva Kubala HavrdovaBianca Weinstock-GuttmanFrancesco PattiAyse AltintasSaloua MrabetRiadh GoudierJihad InshasiVahid ShaygannejadSara EichauW Luke WardHelmut Butzkuevennull nullPublished in: Neurology (2024)
This study provides Class II evidence that patients with POMS treated with natalizumab had a lower risk of relapse than those with fingolimod.